Clinical Trial Update: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Lu-177 dotatate–based PRRT with or without capecitabine for FDG-positive gastro-entero-pancreatic neuroendocrine tumors has been term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastro-entero-pancreatic Neuroendocrine Tumors

Drugs mentioned

• Capecitabine (capecitabine)
• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: Gastro-entero-pancreatic Neuroendocrine Tumors | Phase 2 | Status: TERMINATED